NEULANDLABBSENeuland Laboratories LtdMediumPositive
Announced Tue, 12 May · 17:50 IST

The Record Date for the Purpose of Determining the Shareholder Eligible to receive the final dividend for the financial year ended March 31, 2026, has been fixed as July 24, 2026

Corporate Actions View source PDF

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.5%1-day move
₹17100.00
prior close
₹18305.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-4.3-4.7-4.7-4.3-2.5-3.5-4.7-2.7-2.7-2.5-1.2-0.2+11.0
Up moveDown movePending
AI summary

Neuland Laboratories has fixed July 24, 2026 as the record date for determining shareholders eligible to receive the final dividend of Rs. 34 per equity share (340% on Rs. 10 face value) for FY 2025-26. The company reported strong FY2026 consolidated revenue of Rs. 2,02,299 lakhs, up 37% YoY from Rs. 1,47,684 lakhs. Net profit after tax grew 40% to Rs. 36,400 lakhs from Rs. 26,011 lakhs. Basic EPS improved to Rs. 283.71 from Rs. 202.74. The board also approved capacity expansion of 120.5 KL at Unit 1 in Telangana with an investment of Rs. 143.4 crores. The 42nd AGM is scheduled for August 4, 2026. Statutory auditors issued unmodified opinions on the financial results.

Likely market impact

The 37% revenue growth and 40% profit growth with a Rs. 34 dividend signals strong financial health and shareholder-friendly policies. Investors holding shares by July 24, 2026 will receive the dividend, providing near-term return. The capacity expansion indicates management confidence in sustained demand.